DK1146906T3 - Mukosalt afgivelsessystem - Google Patents

Mukosalt afgivelsessystem

Info

Publication number
DK1146906T3
DK1146906T3 DK00901497.8T DK00901497T DK1146906T3 DK 1146906 T3 DK1146906 T3 DK 1146906T3 DK 00901497 T DK00901497 T DK 00901497T DK 1146906 T3 DK1146906 T3 DK 1146906T3
Authority
DK
Denmark
Prior art keywords
compositions
vaccines
formulations
methods
well
Prior art date
Application number
DK00901497.8T
Other languages
English (en)
Inventor
Rahbek Janne Uldal
Hans Henrik Ipsen
Original Assignee
Alk Abello As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alk Abello As filed Critical Alk Abello As
Application granted granted Critical
Publication of DK1146906T3 publication Critical patent/DK1146906T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Vending Machines For Individual Products (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00901497.8T 1999-02-05 2000-02-04 Mukosalt afgivelsessystem DK1146906T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11889699P 1999-02-05 1999-02-05
DKPA199900155 1999-02-05
PCT/DK2000/000049 WO2000045847A1 (en) 1999-02-05 2000-02-04 Novel mucosal delivery system

Publications (1)

Publication Number Publication Date
DK1146906T3 true DK1146906T3 (da) 2011-10-24

Family

ID=26063341

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00901497.8T DK1146906T3 (da) 1999-02-05 2000-02-04 Mukosalt afgivelsessystem

Country Status (10)

Country Link
EP (1) EP1146906B1 (da)
JP (1) JP2003517452A (da)
CN (1) CN1338947B (da)
AT (1) ATE515258T1 (da)
AU (1) AU771552B2 (da)
CA (1) CA2361377C (da)
DK (1) DK1146906T3 (da)
ES (1) ES2368987T3 (da)
HK (1) HK1041219B (da)
WO (1) WO2000045847A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020051794A1 (en) 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
DE60139404D1 (de) * 2000-08-09 2009-09-10 Alk Abello As Parenterale impfstoff-formulierungen und deren verwendung
CN1758922A (zh) 2003-01-07 2006-04-12 耶达研究及发展有限公司 用于治疗性免疫接种的含共聚物1的滴眼用疫苗
US20060115499A1 (en) * 2004-09-27 2006-06-01 Alk-Abello A/S Liquid allergy vaccine formulation for oromucosal administration
JP5628473B2 (ja) * 2004-11-10 2014-11-19 アルク−アベッロ エイ／エスＡｌｋ−Ａｂｅｌｌｏ Ａ／Ｓ アレルギーワクチンの粘膜投与によるアレルギーの予防治療方法
AU2006299310A1 (en) 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
BRPI0618241A2 (pt) * 2005-11-04 2011-08-23 Alk Abello As uso de um alérgeno para fabricação de uma formulação de vacina lìquida para prevenção ou tratamento de alergia
AU2006310881B2 (en) * 2005-11-04 2012-07-19 Alk-Abello A/S Use of a liquid allergy vaccine formulation for oromucosal administration
WO2009142772A2 (en) 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
CN102441162B (zh) * 2010-10-04 2018-07-24 免疫产品美国股份有限公司 结核病的治疗和预防
EP3556398A1 (en) * 2018-04-16 2019-10-23 Croda Denmark A/S Phytates for use as a biomolecules delivery or adsorption system
CN111658611B (zh) * 2020-04-13 2021-06-01 四川大学 一种基于微乳的疫苗递送***及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3329564A (en) 1965-06-28 1967-07-04 Parke Davis & Co Antacid preparations and means of producing the same
DE2126957B2 (de) 1971-05-29 1977-07-07 Schettler, Hermann, Dr, East Lan sing, Mich (VStA) Verfahren zur herstellung von impfstoffen gegen gaensehepatitis
US4233288A (en) * 1979-03-12 1980-11-11 Cornell John A Gum emulsified liquid package for delivering and preserving liquid content in the mouth
JPS61238728A (ja) 1985-04-16 1986-10-24 Mitsui Norin Kk 茶葉抽出物と活性水酸化アルミニウムとの抗潰瘍性複合体
IL84167A (en) 1986-10-24 1991-04-15 Southern Res Inst Oral delivery of bioactive agents to and through the peyer's patch by use of microencapsulation
JPH02124832A (ja) * 1988-07-08 1990-05-14 Toray Ind Inc インターヘェロンβ組成物
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
JP3132863B2 (ja) * 1991-10-24 2001-02-05 富山化学工業株式会社 徐放性口腔用軟膏
US5360792A (en) 1991-12-20 1994-11-01 Greenwich Pharmaceuticals Incorporated Anti-proliferative and anti-inflammatory compounds: 5- or 6-deoxy hexose monosaccharides having a saturated nitrogen-containing heterocycle at the 5- or 6-position bound through the nitrogen atom
US5972336A (en) * 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
ATE270111T1 (de) 1993-03-18 2004-07-15 Cytimmune Sciences Inc Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren
GB9316745D0 (en) 1993-08-12 1993-09-29 Medeva Holdings Bv Vaccine compositions
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
WO1996040074A2 (en) * 1995-06-07 1996-12-19 Alkermes Controlled Therapeutics, Inc. Device for releasing aggregation-stabilized, biologically active agent
US6221365B1 (en) * 1996-07-26 2001-04-24 American Cyanamid Company NucA protein of Haemophilus influenzae
DK1005368T3 (da) * 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
DE69822542T2 (de) * 1997-04-23 2004-08-05 Pfizer Inc. Verkapslung einer Untereinheit des Bovinen Herpes Virus Typ-1 in wässrigen Lösungsmitteln als Impfstoff.
JPH11216357A (ja) * 1998-02-03 1999-08-10 Tsutsumi Techno Planning Kk 生理活性物質用の吸着担体
JPH11286438A (ja) * 1998-03-31 1999-10-19 Shiseido Co Ltd 徐放性製剤
JPH11302184A (ja) * 1998-04-21 1999-11-02 Taisho Pharmaceut Co Ltd 点鼻用組成物
JPH11322582A (ja) * 1998-05-06 1999-11-24 Dot:Kk 経鼻吸収用鼻粘膜付着・滞留型キャリヤ

Also Published As

Publication number Publication date
ES2368987T3 (es) 2011-11-24
WO2000045847A1 (en) 2000-08-10
ATE515258T1 (de) 2011-07-15
AU2279700A (en) 2000-08-25
AU771552B2 (en) 2004-03-25
EP1146906B1 (en) 2011-07-06
JP2003517452A (ja) 2003-05-27
CA2361377A1 (en) 2000-08-10
WO2000045847A8 (en) 2010-12-02
CN1338947A (zh) 2002-03-06
HK1041219B (zh) 2011-10-21
HK1041219A1 (en) 2002-07-05
CA2361377C (en) 2009-02-03
CN1338947B (zh) 2012-11-14
EP1146906A1 (en) 2001-10-24

Similar Documents

Publication Publication Date Title
CY1110727T1 (el) Παρασκευασματα θετικων κατα gram βακτηριων για τη θεραπεια ασθενειων που περιλαμβανουν μια ανοσολογικη δυσρυθμιση
ES2114616T5 (es) Acidos dicarboxilicos alifaticos insaturados.
DK1146906T3 (da) Mukosalt afgivelsessystem
CY1105221T1 (el) Ιατρικη χρηση θυρεοειδομιμητικων ενωσεων για την θepαπευτικη αγωγη της τριχοπτωσης και φαρμακευτικες συνθεσεις
EE05633B1 (et) Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine
NZ331651A (en) BSW17 peptide immunogens for vaccination against and treatment of allergy
WO2003055513A3 (en) Bacillus subtilis spores to stimulate the immune responses
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
BR0206312A (pt) Composição de vacina, uso sobrenadante de cultura celular de escherichia coli enteroemorrágica (ehec), e, métodos para a geração de uma resposta imunológica em um mamìfero contra um antìgeno de escherichia coli enteroemorrágica (ehec) secretado, e 0157:h7 enteroemorrágica (ehec 0157:h7) secretado, e para a redução da colonização de escherichia coli enteroemorrágica (ehec) em um ruminante
DE69714011T2 (de) Die erzeugung einer immunantwort gegen erwünschte determinanten
ATE179333T1 (de) Immunotherapeutische zubereitung
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
WO1997005899A3 (en) Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
WO2000045849A3 (en) Use of cationic lipids to generate anti-tumor immunity
AU3808795A (en) Water-soluble derivatives of epipodophyllotoxin, process for their preparation, their use as medicinal product and their intended use in anticancer treatments
WO2002058535A3 (en) Use of combretastatin a4 and its prodrugs as an immune enhancing therapy
HUP9902415A2 (hu) Azonnal felszabaduló szilárd beadási formák és eljárás azok előállítására
AU6942896A (en) Use of muteins of wild-type cytokines as immunogens
EP0836480A4 (en) COMPOSITIONS THAT PROVIDE ADP-RIBOSYL TRANSFERASE ACTIVITY AND METHODS FOR THEIR PRODUCTION AND USE
DE69429521D1 (de) Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung
MY137709A (en) Method for obtaining antigenic structures of high cross reactivity and their use in formulations
DE60044539D1 (de) Impfstoff enthaltend lactobacilli zur behandlung von entzündungen der prostata und gutartigen prostata-hyperplasien
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
NZ547521A (en) Protein NMB0928 and use thereof in pharmaceutical formulations
WO2001043772A3 (de) Verfahren und vorrichtung zur herstellung eines autologen immunisierungsimpfstoffes gegen krebserkrankungen (tumorvakzine)